Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans

2009/03/17 by Wolfgang Löscher · 26 citations
Medicine · Neuroscience · #Epilepsy research and treatment #Pharmacological Effects and Toxicity Studies #Neuroscience and Neuropharmacology Research

paper · doi:10.1016/j.ejphar.2009.03.025

Citations

• Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports

Cited by

• The human photosensitive epilepsy model for clinical proof‐of‐principle trials of novel antiseizure medications: 2. Analysis of drug trials and predictive value of the model
• Methylxanthines, seizures, and excitotoxicity. [europepmc]
• Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat. [europepmc]
• Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. [europepmc]
• α-Spinasterol, a TRPV1 receptor antagonist, elevates the seizure threshold in three acute seizure tests in mice. [europepmc]
• Direct Imaging of Hippocampal Epileptiform Calcium Motifs Following Kainic Acid Administration in Freely Behaving Mice. [europepmc]
• Acute Increases in Protein O-GlcNAcylation Dampen Epileptiform Activity in Hippocampus. [europepmc]
• When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. [europepmc]
• Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice. [europepmc]
• Semaphorin 4D promotes inhibitory synapse formation and suppresses seizures in vivo. [europepmc]
• Dysregulated Glucose Metabolism as a Therapeutic Target to Reduce Post-traumatic Epilepsy. [europepmc]
• N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug. [europepmc]
• Polygenic burden in focal and generalized epilepsies. [europepmc]
• Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies. [europepmc]
• Basmisanil, a highly selective GABA A -α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. [europepmc]
• Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation. [europepmc]
• Effect of Ellagic Acid on Seizure Threshold in Two Acute Seizure Tests in Mice. [europepmc]
• OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats. [europepmc]
• Continuous seizure emergency evoked in mice with pharmacological, electrographic, and pathological features distinct from status epilepticus. [europepmc]
• New Phenylglycinamide Derivatives with Hybrid Structure as Candidates for New Broad-Spectrum Anticonvulsants. [europepmc]
• Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand? [europepmc]
• Dogs as a Natural Animal Model of Epilepsy. [europepmc]
• Sigma-1 receptor and seizures. [europepmc]
• Antioxidant Therapy Reduces Oxidative Stress, Restores Na,K-ATPase Function and Induces Neuroprotection in Rodent Models of Seizure and Epilepsy: A Systematic Review and Meta-Analysis. [europepmc]
• Assessing seizure liability in vitro with voltage-sensitive dye imaging in mouse hippocampal slices. [europepmc]
• Challenges and directions in epilepsy diagnostics and therapeutics: Proceedings of the 17th Epilepsy Therapies and Diagnostics Development conference. [europepmc]